Pharmaceutical manufacturers were selected based on the following criteria: 1) medium to large size company; and 2) company has current products and products in development in the area of newer atypical antidepressants and/or antipsychotics. As a result, Janssen, AstraZeneca, Eli Lilly, and GlaxoWellcome (GW) were selected.(1) GW and Eli Lilly are both large companies with current pharmaceuticals directed toward treating depression. Eli Lilly also has an atypical antipsychotic on the market to treat schizophrenia. Medium-sized firms include AstraZeneca and Janssen, both of which offer atypical antipsychotics to treat schizophrenia. Specialized neuropharmaceutical companies (e.g., Neurogen) do not have products in development beyond Phase I, and were excluded for this reason. 1
1 One pharmaceutical company is not listed for confidentiality reasons.
|Originator||Name||Current Indications||Phase III||Mechanism of Action|
|Large Pharmaceutical Companies|
|Eli Lilly and Company||Prozac®||
||Selective serotonin reuptake inhibitor (SSRI)|
|Medium Sized Pharmaceutical Companies|